Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8111404 | 1.00 | ANPEP (0.49) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL10151332 | 0.92 | ANPEP (0.46) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL15671149 | 0.88 | USP2 (0.50) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL22876904 | 0.87 | ANPEP (0.42) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| Bromide SCHEMBL15671179 | 0.86 | KMT2A (0.50) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL611743 | 0.83 | KMT2A (0.53) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL15740339 | 0.81 | USP2 (0.45) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL12846940 | 0.81 | USP2 (0.45) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL11413505 | 0.81 | KMT2A (0.46) | ANPEPUSP2SMN1; SMN2KMT2APKM | |
| SCHEMBL3428839 | 0.81 | USP2 (0.49) | ANPEPUSP2SMN1; SMN2KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-04-05 | — | — | US | disclosed |
| WO-2010141539-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ANPEP 1138/4885USP2 3091/4885SMN1; SMN2 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.